Skip to main content

Table 2 Plasma pharmacokinetic parameters (mean ± SD) for flubendazole (FLBZ) and its reduced metabolite (R-FLBZ), obtained after the intraruminal (i.r.) administration of FLBZ (3.8 mg/kg, n = 6) formulated as a cyclodextrin-based solution (FLBZ-CDs) or a carboximethylcelullose suspension (FLBZ-CMC) to sheep (Experiment 1)

From: Exploring flubendazole formulations for use in sheep. Pharmacokinetic evaluation of a cyclodextrin-based solution

PHARMACOKINETIC PARAMETERS

FLBZ

R-FLBZ

FLBZ-CDs(1)i.r. treatment

FLBZ-CMC(1)i.r. treatment

FLBZ-CDs(2)i.a. treatment

FLBZ-CDs(1)i.r. treatment

FLBZ-CMC(1)i.r. treatment

FLBZ-CDs(2)i.a. treatment

T½abs/for (h)

3.67 ± 1.57

2.92 ± 0.94

0.40 ± 1.43*

3.00 ±1.21

4.95 ± 1.72

0.90 ± 0.30*

Cmax (μg/mL)

0.05 ± 0.01

0.03 ± 0.01

0.07 ± 0.04*

0.23 ± 0.04

0.14 ± 0.03*

0.35 ± 0.09*

Tmax (h)

12.0 ± 3.79

12.5 ± 2.95

2.75 ± 2.36*

10.5 ± 4.93

11.5 ± 1.22

2.75 ± 1.50*

AUC0-t (μg.h/mL)

1.35 ± 0.34

0.78 ± 0.53

0.65 ± 0.29

6.82 ± 1.77

4.92 ± 1.46

3.83 ± 1.86*

T½el (h)

25.8 ± 14.0

19.2 ± 15.1

15.1 ± 8.27*

17.0 ± 5.19

18.4 ± 3.74

6.73 ± 3.70*

MRT (h)

41.6 ± 19.0

34.5 ± 20.3

19.7 ± 9.73*

28.8 ± 8.58

35.4 ± 3.90

10.8 ± 4.07*

  1. The pharmacokinetic parameters obtained after the intra-abomasal (i.a.) administration of FLBZ (3.8 mg/kg, n = 4) formulated as a cyclodextrin-based solution (FLBZ-CDs), is also shown (Experiment 2). T½abs/for: FLBZ absorption or metabolite formation half life; Cmax: peak plasma concentration; Tmax: time to the Cmax; AUC 0-t : Area under the plasma concentration vs. time curve from 0 to the detection time; T½el: elimination half-life; MRT: mean residence time (obtained by non-compartmental analysis of the data). *Significantly different from the FLBZ-CDs i.r. treated group at P < 0.05.
  2. 1Experiment 1: crossover design (n = 6) sheep were treated with the HPβCD-FLBZ solution (FLBZ-CDs) or the CMC-FLBZ suspension (FLBZ-CMC) by the i.r. route at the same dose rate (3.8 mg/kg).
  3. 2Experiment 2: intraabomasal (i.a.) administration of the FLBZ-CDs solution (3.8 mg/kg, n = 4).